# Galvanize Therapeutics

> Galvanize Therapeutics makes pulsed electric field medical devices. Its US-cleared Aliya system ablates soft tissue through percutaneous or endoscopic needles, while its RheOx airway therapy remains investigational in the United States. The company is studying whether the nonthermal approach can preserve tissue structure and produce useful biological responses.

- **Founded:** 2015
- **Headquarters:** Redwood City, United States
- **Founders:** Jonathan Waldstreicher (Founder; former CEO), William S. Krimsky (Co-founder; Chief Medical Officer)
- **Products:** Aliya PEF System, Aliya EX System, INUMI Flex Needle, RheOx System
- **Notable:** US 510(k) clearance for the Aliya PEF system for surgical ablation of soft tissue., 2022 merger of Gala Therapeutics, Galaxy Medical, and Galvanize Therapeutics., 2026 FDA clearance of Aliya EX and first announced commercial procedures.

## Products & services

- **Aliya PEF System** — US 510(k)-cleared system for surgical ablation of soft tissue using nonthermal pulsed electric field energy.
- **Aliya EX System** — New generator with two energy settings, compatible with percutaneous and endoscopic Aliya delivery devices; US cleared in 2026.
- **INUMI Flex Needle** — 21-gauge endoscopic delivery needle for Aliya soft tissue ablation.
- **RheOx System** — Investigational US bronchoscopic generator and single-use catheter designed for symptoms of chronic bronchitis.

## Achievements

- US 510(k) clearance for the Aliya PEF system for surgical ablation of soft tissue.
- 2022 merger of Gala Therapeutics, Galaxy Medical, and Galvanize Therapeutics.
- 2026 FDA clearance of Aliya EX and first announced commercial procedures.
- Peer-reviewed 2026 study reported exploratory immune changes after Aliya PEF in early-stage lung cancer.

## Latest updates

- **2026-08** — Company announced first commercial procedures with Aliya EX and highlighted new exploratory immune evidence.
- **2026-05** — FDA cleared the Aliya EX system for surgical ablation of soft tissue.
- **2025-11** — Company announced publication of six-month AFFINITY findings and added Laura Francis to its board.
- **2025-09** — Raised $100 million Series C led by Sofinnova Partners; Doug Godshall became CEO in 2025.

## Links

- Website: https://galvanizetx.com/
- LinkedIn: https://www.linkedin.com/company/galvanize-therapeutics
- Twitter/X: https://twitter.com/gala_tx_
- Facebook: https://facebook.com/pages/category/Medical---Health/Gala-Therapeutics-2128346067273218/

---

Profile page: https://yespress.io/galvanize
Published by YesPress — https://yespress.io
Last updated: 2026-09-28